Purpose: The applicability of -internal tandem duplications (-ITD) for assessing measurable residual disease (MRD) in acute myeloid leukemia (AML) in complete remission (CR) has been hampered by patient-specific duplications and potential instability of -ITD during relapse. Here, we comprehensively investigated the impact of next-generation sequencing (NGS)-based -ITD MRD detection on treatment outcome in a cohort of patients with newly diagnosed AML in relation to established prognostic factors at diagnosis and other MRD measurements, ie, mutant and multiparameter flow cytometry.
Methods: In 161 patients with de novo -ITD AML, NGS was performed at diagnosis and in CR after intensive remission induction treatment.